Arterial disorder – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 10 Jul 2026 04:04:13 +0000 en-US hourly 1 https://wordpress.org/?v=7.0.1 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Arterial disorder – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on Cerebrolysin and Sodium Chloride for Patients with CADASIL https://clinicaltrials.eu/trial/study-on-cerebrolysin-and-sodium-chloride-for-patients-with-cadasil/ Wed, 29 Apr 2026 14:59:17 +0000 https://clinicaltrials.eu/trial/study-on-cerebrolysin-and-sodium-chloride-for-patients-with-cadasil/ This clinical trial is focused on studying a rare genetic condition called , which stands for Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy. This condition affects the small blood vessels in the brain, leading to strokes and other brain-related issues. The trial will test the effects of a treatment called , which is a solution for injection, to see if it can help patients with CADASIL. Cerebrolysin is compared to a placebo to evaluate its safety and effectiveness.

The purpose of the study is to assess the overall benefits and risks of using Cerebrolysin in patients who have been genetically confirmed to have CADASIL. Participants in the study will receive either Cerebrolysin or a placebo through intravenous infusion, which means the solution is given directly into a vein. The study will take place over two periods, each lasting several months, and will involve regular assessments of the participants’ cognitive abilities, mood, and brain imaging results.

Throughout the study, participants will be monitored to see how they respond to the treatment. The trial aims to gather important information about how Cerebrolysin affects the brain and overall health of people with CADASIL. This research could provide valuable insights into potential new treatments for this challenging condition.

]]> Study on High-Dose Methylprednisolone and Prednisolone for Children with Stroke Due to Focal Cerebral Arteriopathy https://clinicaltrials.eu/trial/study-on-high-dose-methylprednisolone-and-prednisolone-for-children-with-stroke-due-to-focal-cerebral-arteriopathy/ Wed, 29 Apr 2026 14:27:38 +0000 https://clinicaltrials.eu/trial/study-on-high-dose-methylprednisolone-and-prednisolone-for-children-with-stroke-due-to-focal-cerebral-arteriopathy/ This clinical trial is focused on studying the effects of high-dose steroids in children who have experienced a stroke due to an inflammatory condition called focal cerebral arteriopathy. This condition involves the narrowing of blood vessels in the brain, often triggered by an infection. The study aims to determine if early anti-inflammatory treatment with steroids can improve the condition of the blood vessels and prevent further strokes in affected children.

The medications being tested in this study are methylprednisolone and prednisolone. Methylprednisolone is administered intravenously, meaning it is given directly into a vein, while prednisolone is taken orally, in the form of tablets. These medications are being used in addition to the standard care, which includes treatments to prevent blood clots.

Participants in the study will receive either the steroid treatment or a placebo, alongside their usual care. The study will monitor changes in the severity of the arteriopathy over time, as well as any improvements in neurological function and the recurrence of strokes. The study will last for several months, with follow-up assessments to track the progress and outcomes of the treatment.

]]>